chufangao/CTO huggingface dataset:
Clinical trial NCT02922816: FMT for MDRO Colonization After Infection in Renal Transplant Recipients
Official title: A Pilot Study Using Fecal Microbiota Transplant in Renal Transplant Recipients to Eliminate Multidrug-Resistant Organism Colonization After Infection and Examine Gastrointestinal Carriage in a Randomized Placebo-Controlled Design
Acronym: PREMIX
Sponsor: Emory University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: This study was paused and was not resumed due to the COVID-19 pandemic.
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-01
Primary completion date: 2021-12-03
Completion date: 2021-12-03
Plan to share individual participant data: YES
IPD sharing description: De-identified sequencing data may be made available to outside collaborators upon request and approval by study team.
IPD access criteria: Researchers interested in using data collected in this study should submit a methodologically sound protocol to the study PI.
Clinical trial NCT03281876: A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.
Official title: An Observer-blind Study to Evaluate the Efficacy, Safety, Reactogenicity and Immunogenicity of the GSK Biologicals' Investigational Vaccine GSK3277511A When Administered to COPD Patients
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 606.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-27
Primary completion date: 2020-03-26
Completion date: 2020-03-26
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT04368364: A Randomized Control Trial Comparing Analgesic Benefits of Ultrasound-guided Single vs Continuous Quadratus Lumborum Blocks (QLB)vs Intrathecal Morphine(ITM) for Post Cesarean Section Pain
Official title: A Randomized Control Trial Comparing Analgesic Benefits of Ultrasound-guided Single vs Continuous Quadratus Lumborum Blocks vs Intrathecal Morphine for Post Cesarean Section Pain
Sponsor: The University of Texas Health Science Center, Houston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study was stopped early due to a conflicting study in the same patient population at the study location.
Enrollment: 3.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-05-22
Primary completion date: 2020-06-29
Completion date: 2020-06-29
Plan to share individual participant data: NO
Clinical trial NCT03537131: Dapagliflozin During Exercise for the PrevenTion of Hypoglycaemia
Official title: Dapagliflozin During Exercise for the Prevention of Hypoglycaemia in Type 1 Diabetes
Acronym: DEPTH
Sponsor: University of Oxford (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Temporary halt due to COVID-19 pandemic
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-02
Primary completion date: 2021-07-14
Completion date: 2021-07-14
Plan to share individual participant data: YES
Clinical trial NCT02332590: Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)
Official title: A Randomized, Double-blind, Parallel-group Study Assessing the Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab Monotherapy in Patients With Rheumatoid Arthritis
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 369.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-01-28
Primary completion date: 2016-01-20
Completion date: 2020-12-29
Baseline population: Analysis was performed on randomized population that included all participants who received at least 1 dose or part of a dose of Investigational Medicinal Product (IMP).
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT02892149: Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
Official title: Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (INNO2VATE-CONVERSION)
Sponsor: Akebia Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 3554.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-08-31
Primary completion date: 2020-01-16
Completion date: 2020-03-30
Plan to share individual participant data: NO
Clinical trial NCT03150056: Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer
Official title: A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: This study has been terminated due to meeting protocol defined futility.
Enrollment: 73.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-07-18
Primary completion date: 2020-07-31
Completion date: 2021-06-22
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted when justified, for up to another 12 months.
Clinical trial NCT04572893: Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities
Official title: An Open-Label, Exploratory Study of the Safety and Preliminary Efficacy of Danicamtiv in Stable Ambulatory Participants With Primary Dilated Cardiomyopathy Due to Either MYH7 or TTN Variants or Other Causalities
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business objectives have changed
Enrollment: 41.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-04
Primary completion date: 2024-02-22
Completion date: 2024-02-22
Clinical trial NCT04542499: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations
Official title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial)
Acronym: TEMPO-3
Sponsor: Cerevel Therapeutics, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 507.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-27
Primary completion date: 2024-01-29
Completion date: 2024-02-15
Plan to share individual participant data: NO
Clinical trial NCT03985462: Very Small Embryonic-like Stem Cells for Ovary
Official title: Autologous Very Small Embryonic-like Stem Cells(VSELs) for Premature Ovarian Failure
Sponsor: Fuda Cancer Hospital, Guangzhou (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Policy changes have contributed to the failure to carry out smoothly
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-07-03
Primary completion date: 2020-05-30
Completion date: 2020-06-30
Plan to share individual participant data: NO
Clinical trial NCT03645096: Development of Pregnenolone as a Treatment for Depression
Official title: NCCIH Development of Pregnenolone as a Treatment for Depression R61 Phase
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 34.0 (ACTUAL)
Number of arms: 6.0
Start date: 2019-09-01
Primary completion date: 2022-05-31
Completion date: 2022-05-31
Baseline population: The overall number of baseline participants does not differ from the number of participants randomized.
Limitations and caveats: Some fMRI data may have been excluded as a result of motion in the MRI machine.
Plan to share individual participant data: NO
Clinical trial NCT02819843: A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Official title: A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Sponsor: Memorial Sloan Kettering Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 19.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-21
Primary completion date: 2024-02-22
Completion date: 2024-02-22
Clinical trial NCT03985943: Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Sponsor: Galderma R&D (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 941.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-27
Primary completion date: 2021-12-29
Completion date: 2022-08-11
Baseline population: The ITT population consisted of all randomized participants.
Plan to share individual participant data: NO
Clinical trial NCT04254692: Optimizing Recovery in Abdominoplasty
Official title: Randomized Controlled Trial Evaluating Liposomal Bupivacaine Following Abdominoplasty
Sponsor: University of Wisconsin, Madison (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: division wide research suspension
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-05
Primary completion date: 2021-01-21
Completion date: 2021-01-21
Limitations and caveats: study terminated early, not powered for meaningful results
Plan to share individual participant data: NO
Clinical trial NCT04238091: Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata
Official title: Open Label Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Investigator is no longer interested in moving forward with this study
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-19
Primary completion date: 2022-03-02
Completion date: 2022-03-02
Plan to share individual participant data: NO
Clinical trial NCT05524857: Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)
Official title: Phase I Trial of Fedratinib in Combination With Decitabine in Patients With Myeloproliferative Neoplasms in Accelerated and Blast Phase
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Closed by Sponsor
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-28
Primary completion date: 2024-04-09
Completion date: 2024-04-09
Clinical trial NCT04650217: Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing
Official title: Combination Treatment With L-DOPA and Exercise for Mood and Mobility Problems in Late-Life
Sponsor: New York State Psychiatric Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study terminated by sponsor (NIMH)
Enrollment: 1.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-10-07
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Baseline population: 1 participant signed consent for the study but was never randomized into a study group
Plan to share individual participant data: NO
Clinical trial NCT04535817: Xolair Interventional Study in ASD Patients With Comorbid Atopy
Official title: The Effect of Omalizumab (Xolair) on Improving Neuropsychiatric Symptoms in a Subset of ASD Patients With Atopic Disease and Elevated Total IgE Levels
Sponsor: Beth Israel Deaconess Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: We are terminating due to loss of funding because of Covid-19.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-01-01
Primary completion date: 2022-01-01
Completion date: 2022-01-01
Plan to share individual participant data: NO
IPD sharing description: There is no plan to share data with researchers not directly involved in this study and on the research team.
Clinical trial NCT04493541: A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus
Official title: A Phase 1b Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Pharmacokinetics of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 13.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-26
Primary completion date: 2023-04-21
Completion date: 2023-04-21
Clinical trial NCT03213158: Ixazomib for Desensitization
Official title: Ixazomib for Desensitization in Kidney Transplantation
Acronym: IXADES
Sponsor: University of Wisconsin, Madison (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-09-15
Primary completion date: 2021-04-16
Completion date: 2021-04-16
Clinical trial NCT04941183: Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients
Official title: A Randomized, Placebo-controlled, Double-blind, Single-ascending-dose and Multiple-ascending-dose, Phase 1 Study to Assess the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of IV NTR-441 Solution in HV Adults and COVID-19 Patients
Sponsor: Neutrolis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: the emergence of the omicron variant of COVID-19 lead to insufficient enrollment
Enrollment: 52.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-14
Primary completion date: 2022-12-12
Completion date: 2023-06-06
Plan to share individual participant data: NO
Clinical trial NCT02591654: MRI and PET to Assess Pembrolizumab Response
Official title: A Feasibility Study of MRI and PET Imaging to Assess Response to MK-3475 (Pembrolizumab) in Patients With Metastatic Melanoma
Acronym: MPAK
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Poor enrollment
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-10-31
Primary completion date: 2022-10-31
Completion date: 2022-10-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05262517: Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders
Official title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Temporomandibular Disorders (TMD)
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.
Enrollment: 126.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-05
Primary completion date: 2023-05-18
Completion date: 2023-05-18
Baseline population: Analysis population included participants who were enrolled and received at least 1 dose of study medication. Baseline characteristics tabulated by the treated analysis set.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT02289300: A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients
Official title: A Phase II Randomized, Double-Blind, Placebo Controlled, Parallel Study of DCB-BO1202 for Alleviating Liver Fibrosis in HBV Patients With Intermediate Hepatocellular Carcinoma Receiving Loco-regional Therapies
Sponsor: A2 Healthcare Taiwan Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: At sponsor's discretion
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-01-31
Primary completion date: 2021-01-31
Completion date: 2021-12-31
Clinical trial NCT04402866: TD-0903 for ALI Associated With COVID-19
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated With COVID-19
Sponsor: Theravance Biopharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 235.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-06-24
Primary completion date: 2021-04-21
Completion date: 2021-04-21
Baseline population: Part 1: Safety analysis set - all participants who received at least one dose of study drug.~Part 2: Intent-to-Treat (ITT) analysis set - all participants who were randomized into the study.
Plan to share individual participant data: NO
IPD sharing description: Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.
Clinical trial NCT03717012: Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Official title: Study of Pulmonary Rehabilitation In Nintedanib Treated Patients With IPF: Improvements in Activity, Exercise Endurance Time, and QoL
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The trial was terminated prematurely due to difficulties with recruitment because of the COVID-19 pandemic.
Enrollment: 19.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-15
Primary completion date: 2020-03-27
Completion date: 2020-06-10
Baseline population: Randomized set (RS): This patient set includes all randomized patients, whether treated with pulmonary rehabilitation or not.
Limitations and caveats: Trial was terminated prematurely due to difficulties with recruitment and a global BI recruitment hold implemented on 17 March 2020 because of the COVID-19 pandemic. The recruitment rate was slow and the target number of participants to be recruited was not reached. No inferential statistical analysis was performed.
Plan to share individual participant data: UNDECIDED
IPD sharing description: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). Requestors can use the following link http:// trials.boehringer-ingelheim.com/ to:~1. find information in order to request access to clinical study data, for listed studies.~2. request access to clinical study documents that meet criteria, and upon a signed 'Document Sharing Agreement'.
Clinical trial NCT04492254: Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients
Official title: Early Thromboprophylaxis in COVID-19 (ETHIC Trial): an Open Label, Randomized Phase IIIb Trial of Community-based (LMWH) Versus Standard of Care (no Enoxaparin) in COVID-19 Positive Patients
Acronym: ETHIC
Sponsor: Thrombosis Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Average event rate (end point) was much lower than expected. A larger sample size would have been required to maintain same statistical power, which was not achievable in a feasible time scale. No safety concerns were identified with bleeding.
Enrollment: 219.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-27
Primary completion date: 2021-11-29
Completion date: 2021-11-29
Plan to share individual participant data: NO
Clinical trial NCT03316573: Pembrolizumab in Neoplasms or Lymphomas
Official title: A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: Low accrual
Enrollment: 18.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-12-07
Primary completion date: 2022-08-18
Completion date: 2024-08-18
Plan to share individual participant data: NO
Clinical trial NCT04656704: Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease
Official title: Investigating Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: PI no longer pursuing clinical trial
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-01
Primary completion date: 2022-01-01
Completion date: 2022-01-01
Clinical trial NCT01071941: rRp450-Phase I Trial in Liver Metastases and Primary Liver Tumors
Official title: rRp450-Phase I Trial in Liver Metastases and Primary Liver Tumors
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Inadequate funding
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2010-10-31
Primary completion date: 2024-06-30
Completion date: 2024-06-30